Targets › TACSTD2
14 programs from 13 companies in 236 trials: 121 Phase 2, 70 Phase 3, 44 Phase 1, 1 Phase 4; Oncology, Gastroenterology, Genitourinary; next expected readout Nov 2026.
May function as a growth factor receptor. (UniProt, P09758)
Open in Phaseline: the race on TACSTD2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Datopotamab Deruxtecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 4 | Stomatitis; Breast Cancer; Metastatic Non-small Cell Lung Cancer; Non-small Cell Lung Cancer … | Dec 2026 |
| Sichuan Baili Pharmaceutical | BL-B01D1 Anti-TROP2 antibody-drug conjugate | TROP-2, TROP2, TACSTD2 | Phase 3 | Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Non-small Cell Lung Cancer; Epithelial Ovarian Cancer … | Nov 2026 |
| Sichuan Kelun-Biotech Biopharmaceutical | Sacituzumab Govitecan (SKB264) Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer … | Nov 2026 |
| Gilead Sciences | Sacituzumab Govitecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Metastatic Breast Cancer; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer; Locally Advanced or Unresectable Metastatic Breast Cancer … | Dec 2026 |
| Daiichi Sankyo | Datopotamab Deruxtecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Non-small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer; Urothelial Cancer; Advanced or Metastatic NSCLC … | Dec 2026 |
| Merck & Co. (MSD) | Sacituzumab Govitecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Carcinoma, Non-Small-Cell Lung; Gastroesophageal Cancer; Non-small Cell Lung Cancer (NSCLC); Breast Neoplasms … | Jan 2027 |
| RenJi Hospital | [18F]F-RESCA-RCCB6 Trop2/HER2-targeted PET imaging agent | CD70, TROP2, TACSTD2, ERBB2 | Phase 2 | Urologic Neoplasms; Renal Cancer; Solid Tumor; Breast Cancer | Nov 2026 |
| Klus Pharma | Sacituzumab Govitecan (SKB264) Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 2 | Non-small Cell Lung Cancer; Solid Tumor; Epithelial Ovarian Cancer | Dec 2026 |
| Yunnan Cancer Hospital | TTP-ICG fluorescent probe Trop2-targeted NIR-II fluorescent probe | TACSTD2 | Phase 2 | Bladder Cancer (BC) | Jul 2027 |
| Lepu Biopharma | Becotatug Vedotin for Injection Anti-TROP-2 antibody-drug conjugate | TACSTD2 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Dec 2027 |
| Jeeyun Lee | Sonesitatug Vedotin TROP-2-targeting antibody-drug conjugate | TACSTD2 | Phase 2 | Stomach Neoplasms | Oct 2028 |
| RenJi Hospital | [18F]F-RESCA-RB14 Trop2/HER2-targeted PET imaging agent | TACSTD2, ERBB2 | Phase 1 | Breast Cancer | Nov 2026 |
| BiOneCure Therapeutics | BIO-106 anti-TROP-2 antibody-drug conjugate | TACSTD2 | Phase 1 | Advanced Cancer | Apr 2027 |
| Roche | RO7851624 anti-TACSTD2 (TROP-2) antibody-drug conjugate | TACSTD2 | Phase 1 | Relapsed/Refractory Multiple Myeloma | Jul 2030 |
Breast Cancer (23) Non-small Cell Lung Cancer (18) Non-Small Cell Lung Cancer (9) Triple Negative Breast Cancer (8) Cervical Cancer (6) Esophageal Squamous Cell Carcinoma (5) Metastatic Breast Cancer (5) Urothelial Carcinoma (4) Endometrial Cancer (4) Non-small Cell Lung Cancer (NSCLC) (4) Metastatic Breast Cancer ( HER2 Negative) (4) Triple-Negative Breast Cancer (TNBC) (3)
mixed (6), small molecule (5), antibody (3)
RenJi Hospital (2) Sichuan Baili Pharmaceutical (1) Gilead Sciences (1) AstraZeneca (1) Merck & Co. (MSD) (1) Klus Pharma (1) Lepu Biopharma (1) Daiichi Sankyo (1) BiOneCure Therapeutics (1) Yunnan Cancer Hospital (1) Roche (1) Jeeyun Lee (1) Sichuan Kelun-Biotech Biopharmaceutical (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.